| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5666798 | International Journal of Antimicrobial Agents | 2017 | 6 Pages |
â¢Series of N-(substituted-phenyl)-2-[5-(quinoxalin-2-yloxymethyl)-[1,3,4] oxadiazol-2-ylsulfanyl]-acetamides synthesised.â¢In vitro antimicrobial and antiprotozoal activities for the compounds were screened.â¢Structures of the synthesised compounds were elucidated based on spectral and elemental analyses.â¢Lead compound identified in short-term in vivo model in Trypanosoma cruzi.
A new series of N-(substituted-phenyl)-2-[5-(quinoxalin-2-yloxymethyl)-[1,3,4] oxadiazol-2-ylsulfanyl]-acetamides (5a-o) was designed and synthesised from the parent compound 2-hydroxy quinoxaline (1) through a multistep reaction sequence and was characterised by spectral and elemental analyses. All of the compounds synthesised were evaluated for their antimicrobial and antiprotozoal activities. The results revealed that quinoxaline-based 1,3,4-oxadiazoles displayed promising antibacterial, antifungal and anti-Trypanosoma cruzi activities compared with reference drugs, particularly the lead compound 5l in a short-term in vivo model in T. cruzi.
Graphical abstractDownload high-res image (66KB)Download full-size image
